Thinking About a Switch? Your Guide to Compounded GLP-1 and GIP Medications
At GobyMeds, we know that your health journey is uniquely yours. It’s not a straight line, and sometimes, the path needs to change to help you reach your goals. If you're currently on a compounded GLP-1 medication like semaglutide and are curious about other options, you're in the right place!
Many of our members have great success with compounded GLP-1s, but for some, switching to a dual-agonist medication like compounded tirzepatide (which acts on both GLP-1 and GIP receptors) can be a game-changer. Let's explore what that switch could look like for you.
What’s the Difference, Really? GLP-1 vs. GLP-1/GIP
It sounds technical, but the concept is pretty simple. Both medications work by mimicking the natural hormones your body releases after you eat, which helps control hunger and manage blood sugar.
The key difference is in their approach:
- Compounded Semaglutide (GLP-1): This medication targets one specific hormone receptor called GLP-1.
- Compounded Tirzepatide (GLP-1/GIP): This is a dual-action medication that targets both GLP-1 and GIP receptors.
Think of it like having two tools instead of one. For some individuals, this dual-action can lead to better results.
Why Consider Making the Switch?
Your wellness journey is personal, and so are the reasons for exploring a new medication. People consider switching from a GLP-1 to a dual GLP-1/GIP for a few common reasons, always in consultation with their provider.
- You've Hit a Plateau: Sometimes, your body gets used to a medication, and your amazing progress might slow down. Switching to a medication with a different mechanism, like tirzepatide, could help re-ignite your results.
- Managing Side Effects: While many people tolerate GLP-1s well, some experience side effects like nausea. Occasionally, patients find that the side effects of Tirzepatide are different or more manageable for them.
- Aligning with Your Goals: If your goals include significant weight management and enhanced blood sugar control, the dual-action power of tirzepatide might be a better fit for your specific needs.
What Does the Research Say?
The excitement around tirzepatide is backed by impressive clinical research.
Multiple studies have shown that tirzepatide can lead to substantial weight loss. The landmark SURMOUNT-1 clinical trial, for example, found that participants with obesity or who were overweight lost an average of 15% to 22.5% of their body weight over 72 weeks.
Even more compelling are the head-to-head comparisons. A study published in The New England Journal of Medicinefound that participants on tirzepatide lost a greater percentage of their body weight than those on semaglutide.This suggests that for many, the dual-action approach of tirzepatide can lead to more significant results.
Beyond the numbers on the scale, research has also highlighted tirzepatide positive impact on other aspects of metabolic health, including significant reductions in waist circumference and improved blood sugar control.
The GobyMeds Promise: A Seamless Transition
Thinking about changing your plan shouldn't be stressful. Here at GobyMeds, your success is our mission. Because we offer personalized, compounded GLP-1 and GIP medications, making a switch is simple and hassle-free.
You're never locked into a single path. Just have a conversation with your dedicated GobyMeds care team. Your provider will listen to your experience, discuss your goals, and if a switch is right for you, they will update your personalized plan and provide you with new instructions. No need to find a new provider or start from scratch. We’re with you every step of the way.
Ready to see if a personalized plan is right for you? Start Your Consultation Today!
Disclaimer: This information is for educational purposes only and does not constitute medical advice. Please consult with a qualified healthcare provider for any health concerns or before making any decisions related to your health or treatment.
Compounded Semaglutide and Tirzepatide are not FDA-approved. These medications are prepared by state-licensed 503(a) and 503(b) compounding pharmacies and are not affiliated with or endorsed by Novo Nordisk™ (makers of Ozempic®/Wegovy®) or Eli Lilly and Company™ (makers of Mounjaro®/Zepbound®).
